mupirocin (bactroban) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mupirocin (BACTROBAN®) is an antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyltransfer RNA (tRNA) synthetase. It also severely inhibits RNA synthesis. DNA and cell wall peptidoglycan synthesis are inhibited to a lesser extent and interference with these processes is considered to be a secondary effect. Mupirocin is bactericidal at concentrations achieved by topical administration.   NCATS

Chemistry

  • SMILES: C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.O.O.[Ca+2]
  • InChIKey: DDHVILIIHBIMQU-YJGQQKNPSA-L
  • Mol. Mass: 1075.35
  • ALogP: 2.59
  • ChEMBL Molecules:
    mupirocin calcium  
    mupirocin calcium  
    mupirocin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1894 - $10.9011

Australia

$6.6831 - $10.4821
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3- [(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid | bactroban | brl 4910a | brl-4910a | brl-4910f | centany | mupirocin | mupirocina | mupirocin calcium | mupirocin calcium dihydrate | mupirocine | mupirocinum | mupricin | pseudomonic acid | pseudomonic acid a | td1414 | turixin

Organizations (117)

Research & Development (109)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (34)

Approved Indications (3)


 

Impetigo

Infections

Skin Diseases, Infectious (approved 1987)

Experimental Indications - Clinical Trial Phases 1-4 (33)


 

Abscess (Phase 4)

Bacterial Infections (Phase 4)

Catheter-Related Infections (Phase 2/Phase 3)

Colonic Neoplasms (Phase 3)

Cross Infection (Phase 4)

Cystic Fibrosis (Phase 2)

Dermatitis, Atopic (Phase 4)

Dialysis (Phase 4)

Enterobacteriaceae Infections (Phase 4)

Epistaxis (Phase 3)

General Surgery (Phase 4)

Hemangioma (Phase 2)

Hemodialysis, Home (Phase 4)

HIV Infections (Phase 4)

Impetigo (Phase 3)

Infections (Phase 4)

Kidney Failure, Chronic (Phase 4)

Methicillin-Resistant Staphylococcus aureus (Phase 4)

Microbiota (Phase 4)

Mucositis (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Peptic Ulcer (Phase 1)

Peritoneal Dialysis (Phase 4)

Quality of Life (Phase 3)

Radiodermatitis (Phase 2/Phase 3)

Sinusitis (Phase 4)

Staphylococcal Infections (Phase 4)

Staphylococcus (Phase 2)

Staphylococcus aureus (Phase 4)

Surgical Wound Infection (Phase 4)

Telangiectasia, Hereditary Hemorrhagic (Phase 3)

Traumatology (Phase 3)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 70
  • # of Trial Organizations: 109

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue